UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Investigational therapies for treating symptoms of lower extremity peripheral artery disease

Author
Emile R Mohler III, MD
Section Editors
Denis L Clement, MD, PhD
John F Eidt, MD
Joseph L Mills, Sr, MD
Deputy Editor
Kathryn A Collins, MD, PhD, FACS

INTRODUCTION

Pharmacologic therapies used in the treatment of patients with lower extremity peripheral artery disease (PAD) are primarily aimed at improving symptoms or slowing the progression of the disease. Therapies under investigation that may become useful for improving symptoms of claudication to avoid the need for revascularization, promote healing of ischemic ulcers, or alter perception of ischemic pain in patients who are poor candidates or who have failed revascularization attempts are reviewed here. The clinical use of these agents is not yet recommended.

For patients with claudication, convincing evidence of benefit of pharmacologic agents for improving symptoms is available only for cilostazol and naftidrofuryl among the myriad of agents that have been evaluated [1-4]. Recommendations for these and other potentially beneficial pharmacologic agents are discussed separately. (See "Management of claudication", section on 'Beneficial'.)

The best therapeutic option for patients with advanced PAD (eg, rest pain, ischemic ulceration, gangrene) is revascularization (percutaneous or surgical). However, many patients are poor candidates for revascularization due to severe medical comorbidities. (See "Treatment of chronic lower extremity critical limb ischemia".)

Other pharmacologic therapy aimed at reducing the risk for future cardiovascular events in patients with PAD, and which may also limit progression of disease, are reviewed elsewhere. (See "Overview of lower extremity peripheral artery disease" and "Prevention of cardiovascular disease events in those with established disease or at high risk".)

PHARMACOLOGIC AGENTS

The pathophysiology of the impairments associated with ischemia is complex and provides multiple potential targets for novel drug therapies [5,6]. Potential future pharmacologic therapies that remain to be proven beneficial for the treatment of symptoms associated with lower extremity peripheral artery disease, including claudication, are presented below in alphabetical order. These therapies may be targeted either to improving symptoms of claudication or to more severe manifestations of ischemia, such as ischemic rest pain, ulceration, or gangrene.  

                

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Wed Jul 06 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007; 45 Suppl S:S5.
  2. 2011 WRITING GROUP MEMBERS, 2005 WRITING COMMITTEE MEMBERS, ACCF/AHA TASK FORCE MEMBERS. 2011 ACCF/AHA Focused Update of the Guideline for the Management of patients with peripheral artery disease (Updating the 2005 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011; 124:2020.
  3. Sobel M, Verhaeghe R, American College of Chest Physicians, American College of Chest Physicians. Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:815S.
  4. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113:e463.
  5. Brass EP. Intermittent claudication: new targets for drug development. Drugs 2013; 73:999.
  6. Shalhoub J, Davies AH. Adjunctive pharmacotherapies for intermittent claudication--NICE guidance. Heart 2012; 98:244.
  7. Kaperonis EA, Liapis CD, Kakisis JD, et al. Inflammation and Chlamydia pneumoniae infection correlate with the severity of peripheral arterial disease. Eur J Vasc Endovasc Surg 2006; 31:509.
  8. Vainas T, Stassen FR, Schurink GW, et al. Secondary prevention of atherosclerosis through chlamydia pneumoniae eradication (SPACE Trial): a randomised clinical trial in patients with peripheral arterial disease. Eur J Vasc Endovasc Surg 2005; 29:403.
  9. Wiesli P, Czerwenka W, Meniconi A, et al. Roxithromycin treatment prevents progression of peripheral arterial occlusive disease in Chlamydia pneumoniae seropositive men: a randomized, double-blind, placebo-controlled trial. Circulation 2002; 105:2646.
  10. Jaff MR, Dale RA, Creager MA, et al. Anti-chlamydial antibiotic therapy for symptom improvement in peripheral artery disease: prospective evaluation of rifalazil effect on vascular symptoms of intermittent claudication and other endpoints in Chlamydia pneumoniae seropositive patients (PROVIDENCE-1). Circulation 2009; 119:452.
  11. Kleijnen J, Mackerras D. Vitamin E for intermittent claudication. Cochrane Database Syst Rev 2000; :CD000987.
  12. Carrero JJ, López-Huertas E, Salmerón LM, et al. Daily supplementation with (n-3) PUFAs, oleic acid, folic acid, and vitamins B-6 and E increases pain-free walking distance and improves risk factors in men with peripheral vascular disease. J Nutr 2005; 135:1393.
  13. Violi F, Loffredo L, Mancini A, Marcoccia A. Antioxidants in peripheral arterial disease. Curr Drug Targets 2003; 4:651.
  14. Arosio E, De Marchi S, Zannoni M, et al. Effect of glutathione infusion on leg arterial circulation, cutaneous microcirculation, and pain-free walking distance in patients with peripheral obstructive arterial disease: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2002; 77:754.
  15. Mohler ER 3rd, Gainer JL, Whitten K, et al. Evaluation of trans sodium crocetinate on safety and exercise performance in patients with peripheral artery disease and intermittent claudication. Vasc Med 2011; 16:346.
  16. Luyt CE, Lepailleur-Enouf D, Gaultier CJ, et al. Involvement of the endothelin system in experimental critical hind limb ischemia. Mol Med 2000; 6:947.
  17. Herrick AL. Contemporary management of Raynaud's phenomenon and digital ischaemic complications. Curr Opin Rheumatol 2011; 23:555.
  18. Thonhofer R, Siegel C, Hafner F, et al. Successful bosentan treatment of critical ischaemia induced by vasculitis in an SCLE patient. Rheumatology (Oxford) 2008; 47:1729.
  19. Korn JH, Mayes M, Matucci Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004; 50:3985.
  20. Matucci-Cerinic M, Denton CP, Furst DE, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2011; 70:32.
  21. De Haro J, Bleda S, Varela C, et al. Effect of Bosentan on Claudication Distance and Endothelium-Dependent Vasodilation in Hispanic Patients With Peripheral Arterial Disease. Am J Cardiol 2016; 117:295.
  22. Ernst E, Kollar L, Matrai A. [Hemodilution in peripheral arterial occlusive disease. Placebo controlled randomized double-blind study with hydroxyethyl starch or dextran]. Acta Med Austriaca 1991; 18 Suppl 1:27.
  23. Kiesewetter H, Blume J, Jung F, et al. Haemodilution with medium molecular weight hydroxyethyl starch in patients with peripheral arterial occlusive disease stage IIb. J Intern Med 1990; 227:107.
  24. Höffkes HG, Ehrly AM. Microcirculatory long-term effects after hypervolaemic and isovolaemic haemodilution in patients with intermittent claudication. Presse Med 1994; 23:657.
  25. Bag S, Behera A, Khandelwal N, et al. Improvement in Blood Supply After "Heparin-Dextran" Therapy in Patients of Buerger's Disease with Critical Limb Ischemia. Indian J Surg 2013; 75:462.
  26. Urge J, Strojil J, Utíkal P. Pharmacotherapeutical approaches to decreasing hematocrit and increasing claudication distance in diabetic patients with peripheral vascular disease. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2005; 149:267.
  27. Celsing F, Eriksson M, Markström U, Rosfors S. Clinical and hemodynamic effects of stepwise lowering of hemoglobin concentration in patients with intermittent claudication. Angiology 1994; 45:43.
  28. Domanchuk K, Ferrucci L, Guralnik JM, et al. Progenitor cell release plus exercise to improve functional performance in peripheral artery disease: the PROPEL Study. Contemp Clin Trials 2013; 36:502.
  29. Marfella R, Luongo C, Coppola A, et al. Use of a non-specific immunomodulation therapy as a therapeutic vasculogenesis strategy in no-option critical limb ischemia patients. Atherosclerosis 2010; 208:473.
  30. Losordo DW, Kibbe MR, Mendelsohn F, et al. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circ Cardiovasc Interv 2012; 5:821.
  31. Fadini GP, Sartore S, Albiero M, et al. Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopathy. Arterioscler Thromb Vasc Biol 2006; 26:2140.
  32. Shaffer RG, Greene S, Arshi A, et al. Effect of acute exercise on endothelial progenitor cells in patients with peripheral arterial disease. Vasc Med 2006; 11:219.
  33. Schlager O, Giurgea A, Schuhfried O, et al. Exercise training increases endothelial progenitor cells and decreases asymmetric dimethylarginine in peripheral arterial disease: a randomized controlled trial. Atherosclerosis 2011; 217:240.
  34. Turton EP, Scott DJ, Carding SR. Immune modulation therapy. Eur J Vasc Endovasc Surg 2002; 24:466.
  35. McGrath C, Robb R, Lucas AJ, et al. A randomised, double blind, placebo-controlled study to determine the efficacy of immune modulation therapy in the treatment of patients suffering from peripheral arterial occlusive disease with intermittent claudication. Eur J Vasc Endovasc Surg 2002; 23:381.
  36. Sasaki Y, Suzuki H, Itoh S, et al. K-134, a phosphodiesterase 3 inhibitor, improves gait disturbance and hindlimb blood flow impairment in rat peripheral artery disease models. Eur J Pharmacol 2012; 689:132.
  37. Yoshida H, Itoh S, Hara T, et al. A phosphodiesterase 3 inhibitor, K-134, improves hindlimb skeletal muscle circulation in rat models of peripheral arterial disease. Atherosclerosis 2012; 221:84.
  38. Ishiwata N, Noguchi K, Kawanishi M, et al. NT-702 (parogrelil hydrochloride, NM-702), a novel and potent phosphodiesterase inhibitor, improves reduced walking distance and lowered hindlimb plantar surface temperature in a rat experimental intermittent claudication model. Life Sci 2007; 81:970.
  39. Brass EP, Anthony R, Cobb FR, et al. The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J Am Coll Cardiol 2006; 48:2539.
  40. Brass EP, Cooper LT, Morgan RE, Hiatt WR. A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. J Vasc Surg 2012; 55:381.
  41. Lewis RJ, Connor JT, Teerlink JR, et al. Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. Trials 2011; 12:134.
  42. Robertson L, Andras A. Prostanoids for intermittent claudication. Cochrane Database Syst Rev 2013; :CD000986.
  43. Ruffolo AJ, Romano M, Ciapponi A. Prostanoids for critical limb ischaemia. Cochrane Database Syst Rev 2010; :CD006544.
  44. Belch JJ, Bell PR, Creissen D, et al. Randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of AS-013, a prostaglandin E1 prodrug, in patients with intermittent claudication. Circulation 1997; 95:2298.
  45. Luzzi R, Belcaro G, Ippolito E, et al. [Severe intermittent claudication: PGE1 treatment. A 40-week registry, efficacy and costs]. Minerva Cardioangiol 2012; 60:405.
  46. Prostanoids for chronic critical leg ischemia. A randomized, controlled, open-label trial with prostaglandin E1. The ICAI Study Group. Ischemia Cronica degli Arti Inferiori. Ann Intern Med 1999; 130:412.
  47. Nehler MR, Brass EP, Anthony R, et al. Adjunctive parenteral therapy with lipo-ecraprost, a prostaglandin E1 analog, in patients with critical limb ischemia undergoing distal revascularization does not improve 6-month outcomes. J Vasc Surg 2007; 45:953.
  48. Brass EP, Anthony R, Dormandy J, et al. Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia. J Vasc Surg 2006; 43:752.
  49. Creager MA, Pande RL, Hiatt WR. A randomized trial of iloprost in patients with intermittent claudication. Vasc Med 2008; 13:5.
  50. Mohler ER 3rd, Klugherz B, Goldman R, et al. Trial of a novel prostacyclin analog, UT-15, in patients with severe intermittent claudication. Vasc Med 2000; 5:231.
  51. Berman S, Quick R, Yoder P, et al. Treprostinil sodium (Remodulin), a prostacyclin analog, in the treatment of critical limb ischemia: open-label study. Vascular 2006; 14:142.
  52. Fernandez B, Strootman D. The prostacyclin analog, treprostinil sodium, provides symptom relief in severe Buerger's disease--a case report and review of literature. Angiology 2006; 57:99.
  53. Lièvre M, Morand S, Besse B, et al. Oral Beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group. Circulation 2000; 102:426.
  54. Mohler ER 3rd, Hiatt WR, Olin JW, et al. Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin I2 analogue: a double-blinded, randomized, controlled trial. J Am Coll Cardiol 2003; 41:1679.
  55. Shahin Y, Cockcroft JR, Chetter IC. Randomized clinical trial of angiotensin-converting enzyme inhibitor, ramipril, in patients with intermittent claudication. Br J Surg 2013; 100:1154.
  56. Ma A, Garland WT, Smith WB, et al. A pilot study of ranolazine in patients with intermittent claudication. Int Angiol 2006; 25:361.
  57. Kumar D, Branch BG, Pattillo CB, et al. Chronic sodium nitrite therapy augments ischemia-induced angiogenesis and arteriogenesis. Proc Natl Acad Sci U S A 2008; 105:7540.
  58. Mohler ER 3rd, Hiatt WR, Gornik HL, et al. Sodium nitrite in patients with peripheral artery disease and diabetes mellitus: safety, walking distance and endothelial function. Vasc Med 2014; 19:9.
  59. Dezfulian C, Alekseyenko A, Dave KR, et al. Nitrite therapy is neuroprotective and safe in cardiac arrest survivors. Nitric Oxide 2012; 26:241.
  60. Dezfulian C, Shiva S, Alekseyenko A, et al. Nitrite therapy after cardiac arrest reduces reactive oxygen species generation, improves cardiac and neurological function, and enhances survival via reversible inhibition of mitochondrial complex I. Circulation 2009; 120:897.
  61. Chiodi H, Mohler JG. Nonautocatalytic methemoglobin formation by sodium nitrite under aerobic and anaerobic conditions. Environ Res 1987; 44:45.
  62. Ruiz-Salmeron R, de la Cuesta-Diaz A, Constantino-Bermejo M, et al. Angiographic demonstration of neoangiogenesis after intra-arterial infusion of autologous bone marrow mononuclear cells in diabetic patients with critical limb ischemia. Cell Transplant 2011; 20:1629.
  63. Lasala GP, Minguell JJ. Vascular disease and stem cell therapies. Br Med Bull 2011; 98:187.
  64. Idei N, Soga J, Hata T, et al. Autologous bone-marrow mononuclear cell implantation reduces long-term major amputation risk in patients with critical limb ischemia: a comparison of atherosclerotic peripheral arterial disease and Buerger disease. Circ Cardiovasc Interv 2011; 4:15.
  65. Lee HC, An SG, Lee HW, et al. Safety and effect of adipose tissue-derived stem cell implantation in patients with critical limb ischemia: a pilot study. Circ J 2012; 76:1750.
  66. Bura A, Planat-Benard V, Bourin P, et al. Phase I trial: the use of autologous cultured adipose-derived stroma/stem cells to treat patients with non-revascularizable critical limb ischemia. Cytotherapy 2014; 16:245.
  67. Zhi K, Gao Z, Bai J, et al. Application of adipose-derived stem cells in critical limb ischemia. Front Biosci (Landmark Ed) 2014; 19:768.
  68. Cai A, Qiu R, Li L, et al. Atorvastatin treatment of rats with ischemia-reperfusion injury improves adipose-derived mesenchymal stem cell migration and survival via the SDF-1α/CXCR-4 axis. PLoS One 2013; 8:e79100.
  69. Acosta L, Hmadcha A, Escacena N, et al. Adipose mesenchymal stromal cells isolated from type 2 diabetic patients display reduced fibrinolytic activity. Diabetes 2013; 62:4266.
  70. Prather WR, Toren A, Meiron M, et al. The role of placental-derived adherent stromal cell (PLX-PAD) in the treatment of critical limb ischemia. Cytotherapy 2009; 11:427.
  71. Moazzami K, Majdzadeh R, Nedjat S. Local intramuscular transplantation of autologous mononuclear cells for critical lower limb ischaemia. Cochrane Database Syst Rev 2011; :CD008347.
  72. Benoit E, O'Donnell TF, Patel AN. Safety and efficacy of autologous cell therapy in critical limb ischemia: a systematic review. Cell Transplant 2013; 22:545.
  73. Teraa M, Sprengers RW, van der Graaf Y, et al. Autologous bone marrow-derived cell therapy in patients with critical limb ischemia: a meta-analysis of randomized controlled clinical trials. Ann Surg 2013; 258:922.
  74. Poole J, Mavromatis K, Binongo JN, et al. Effect of progenitor cell mobilization with granulocyte-macrophage colony-stimulating factor in patients with peripheral artery disease: a randomized clinical trial. JAMA 2013; 310:2631.
  75. van Royen N, Schirmer SH, Atasever B, et al. START Trial: a pilot study on STimulation of ARTeriogenesis using subcutaneous application of granulocyte-macrophage colony-stimulating factor as a new treatment for peripheral vascular disease. Circulation 2005; 112:1040.
  76. Balber AE. Concise review: aldehyde dehydrogenase bright stem and progenitor cell populations from normal tissues: characteristics, activities, and emerging uses in regenerative medicine. Stem Cells 2011; 29:570.
  77. Keller LH. Bone marrow-derived aldehyde dehydrogenase-bright stem and progenitor cells for ischemic repair. Congest Heart Fail 2009; 15:202.
  78. Klepanec A, Mistrik M, Altaner C, et al. No difference in intra-arterial and intramuscular delivery of autologous bone marrow cells in patients with advanced critical limb ischemia. Cell Transplant 2012; 21:1909.
  79. Pacilli A, Faggioli G, Stella A, Pasquinelli G. An update on therapeutic angiogenesis for peripheral vascular disease. Ann Vasc Surg 2010; 24:258.
  80. Ouma GO, Jonas RA, Usman MH, Mohler ER 3rd. Targets and delivery methods for therapeutic angiogenesis in peripheral artery disease. Vasc Med 2012; 17:174.
  81. Kim AK, Kim MH, Kim S, et al. Stem-cell therapy for peripheral arterial occlusive disease. Eur J Vasc Endovasc Surg 2011; 42:667.
  82. Moazzami K, Moazzami B, Roohi A, et al. Local intramuscular transplantation of autologous mononuclear cells for critical lower limb ischaemia. Cochrane Database Syst Rev 2014; :CD008347.
  83. Huang P, Li S, Han M, et al. Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care 2005; 28:2155.
  84. Tateishi-Yuyama E, Matsubara H, Murohara T, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 2002; 360:427.
  85. Dash NR, Dash SN, Routray P, et al. Targeting nonhealing ulcers of lower extremity in human through autologous bone marrow-derived mesenchymal stem cells. Rejuvenation Res 2009; 12:359.
  86. Ozturk A, Kucukardali Y, Tangi F, et al. Therapeutical potential of autologous peripheral blood mononuclear cell transplantation in patients with type 2 diabetic critical limb ischemia. J Diabetes Complications 2012; 26:29.
  87. Debin L,Youzhao J, Ziwen L, et al. Autologous transplantation of bone marrow mesenchymal stem cells on diabetic patients with lower limb ischemia. J Med Coll PLA 2008;23:106.
  88. Barc P, Skora J, Pupka A, et al. Bone-marrow cells in therapy of critical limb ischaemia of lower extremities-Own experience. Acta Angiolog 2006;12:155.
  89. Arai M, Misao Y, Nagai H, et al. Granulocyte colony-stimulating factor: a noninvasive regeneration therapy for treating atherosclerotic peripheral artery disease. Circ J 2006; 70:1093.
  90. Walter DH, Krankenberg H, Balzer JO, et al. Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: a randomized-start, placebo-controlled pilot trial (PROVASA). Circ Cardiovasc Interv 2011; 4:26.
  91. Benoit E, O'Donnell TF Jr, Iafrati MD, et al. The role of amputation as an outcome measure in cellular therapy for critical limb ischemia: implications for clinical trial design. J Transl Med 2011; 9:165.
  92. Lu D, Chen B, Liang Z, et al. Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial. Diabetes Res Clin Pract 2011; 92:26.
  93. Powell RJ, Marston WA, Berceli SA, et al. Cellular therapy with Ixmyelocel-T to treat critical limb ischemia: the randomized, double-blind, placebo-controlled RESTORE-CLI trial. Mol Ther 2012; 20:1280.
  94. Procházka V, Gumulec J, Jalůvka F, et al. Cell therapy, a new standard in management of chronic critical limb ischemia and foot ulcer. Cell Transplant 2010; 19:1413.
  95. Teraa M, Sprengers RW, Schutgens RE, et al. Effect of repetitive intra-arterial infusion of bone marrow mononuclear cells in patients with no-option limb ischemia: the randomized, double-blind, placebo-controlled Rejuvenating Endothelial Progenitor Cells via Transcutaneous Intra-arterial Supplementation (JUVENTAS) trial. Circulation 2015; 131:851.
  96. Peeters Weem SM, Teraa M, de Borst GJ, et al. Bone Marrow derived Cell Therapy in Critical Limb Ischemia: A Meta-analysis of Randomized Placebo Controlled Trials. Eur J Vasc Endovasc Surg 2015; 50:775.
  97. Mohammadzadeh L, Samedanifard SH, Keshavarzi A, et al. Therapeutic outcomes of transplanting autologous granulocyte colony-stimulating factor-mobilised peripheral mononuclear cells in diabetic patients with critical limb ischaemia. Exp Clin Endocrinol Diabetes 2013; 121:48.
  98. Perin EC, Silva GV, Zheng Y, et al. Randomized, double-blind pilot study of transendocardial injection of autologous aldehyde dehydrogenase-bright stem cells in patients with ischemic heart failure. Am Heart J 2012; 163:415.
  99. Perin EC, Silva G, Gahremanpour A, et al. A randomized, controlled study of autologous therapy with bone marrow-derived aldehyde dehydrogenase bright cells in patients with critical limb ischemia. Catheter Cardiovasc Interv 2011; 78:1060.
  100. Franz RW, Shah KJ, Johnson JD, et al. Short- to mid-term results using autologous bone-marrow mononuclear cell implantation therapy as a limb salvage procedure in patients with severe peripheral arterial disease. Vasc Endovascular Surg 2011; 45:398.
  101. Lasala GP, Silva JA, Minguell JJ. Therapeutic angiogenesis in patients with severe limb ischemia by transplantation of a combination stem cell product. J Thorac Cardiovasc Surg 2012; 144:377.
  102. Gupta PK, Chullikana A, Parakh R, et al. A double blind randomized placebo controlled phase I/II study assessing the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell in critical limb ischemia. J Transl Med 2013; 11:143.
  103. Shimamura M, Nakagami H, Taniyama Y, Morishita R. Gene therapy for peripheral arterial disease. Expert Opin Biol Ther 2014; 14:1175.
  104. Kalka C, Masuda H, Takahashi T, et al. Vascular endothelial growth factor(165) gene transfer augments circulating endothelial progenitor cells in human subjects. Circ Res 2000; 86:1198.
  105. Takeshita S, Zheng LP, Brogi E, et al. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 1994; 93:662.
  106. Lederman RJ, Mendelsohn FO, Anderson RD, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 2002; 359:2053.
  107. Baumgartner I, Pieczek A, Manor O, et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998; 97:1114.
  108. Rajagopalan S, Mohler ER 3rd, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003; 108:1933.
  109. De Haro J, Acin F, Lopez-Quintana A, et al. Meta-analysis of randomized, controlled clinical trials in angiogenesis: gene and cell therapy in peripheral arterial disease. Heart Vessels 2009; 24:321.
  110. Creager MA, Olin JW, Belch JJ, et al. Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication. Circulation 2011; 124:1765.
  111. Rajagopalan S, Mohler E 3rd, Lederman RJ, et al. Regional Angiogenesis with Vascular Endothelial Growth Factor (VEGF) in peripheral arterial disease: Design of the RAVE trial. Am Heart J 2003; 145:1114.
  112. Grossman PM, Mendelsohn F, Henry TD, et al. Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease. Am Heart J 2007; 153:874.
  113. Belch J, Hiatt WR, Baumgartner I, et al. Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet 2011; 377:1929.
  114. Kusumanto YH, van Weel V, Mulder NH, et al. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial. Hum Gene Ther 2006; 17:683.
  115. Rajagopalan S, Olin J, Deitcher S, et al. Use of a constitutively active hypoxia-inducible factor-1alpha transgene as a therapeutic strategy in no-option critical limb ischemia patients: phase I dose-escalation experience. Circulation 2007; 115:1234.
  116. Nikol S, Baumgartner I, Van Belle E, et al. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther 2008; 16:972.
  117. Powell RJ, Simons M, Mendelsohn FO, et al. Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation 2008; 118:58.
  118. Powell RJ, Goodney P, Mendelsohn FO, et al. Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: results of the HGF-0205 trial. J Vasc Surg 2010; 52:1525.
  119. Shigematsu H, Yasuda K, Iwai T, et al. Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther 2010; 17:1152.
  120. Anghel A, Taranu G, Seclaman E, et al. Safety of vascular endothelial and hepatocyte growth factor gene therapy in patients with critical limb ischemia. Curr Neurovasc Res 2011; 8:183.
  121. Mäkinen K, Manninen H, Hedman M, et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol Ther 2002; 6:127.
  122. Hammer A, Steiner S. Gene therapy for therapeutic angiogenesis in peripheral arterial disease - a systematic review and meta-analysis of randomized, controlled trials. Vasa 2013; 42:331.
  123. Hammer A, Koppensteiner R, Steiner S, et al. Dark chocolate and vascular function in patients with peripheral artery disease: a randomized, controlled cross-over trial. Clin Hemorheol Microcirc 2015; 59:145.
  124. Loffredo L, Perri L, Catasca E, et al. Dark chocolate acutely improves walking autonomy in patients with peripheral artery disease. J Am Heart Assoc 2014; 3.
  125. Horsch S, Claeys L. Epidural spinal cord stimulation in the treatment of severe peripheral arterial occlusive disease. Ann Vasc Surg 1994; 8:468.
  126. Mingoli A, Sciacca V, Tamorri M, et al. Clinical results of epidural spinal cord electrical stimulation in patients affected with limb-threatening chronic arterial obstructive disease. Angiology 1993; 44:21.
  127. Ubbink DT, Vermeulen H. Spinal cord stimulation for non-reconstructable chronic critical leg ischaemia. Cochrane Database Syst Rev 2013; :CD004001.